Hereditary Neuropathy Foundation Re-Launches One-of-A-Kind Patient Registry for Charcot-Marie-Tooth Disease Research

by | Apr 12, 2023 | 0 comments

Hereditary Neuropathy Foundation Re-Launches One-of-A-Kind Patient Registry for Charcot-Marie-Tooth Disease Research

This user-friendly platform allows patients, caregivers, clinicians, and researchers the ability to manage health data to elevate CMT patient care.

The Hereditary Neuropathy Foundation (HNF), together with Across Healthcare, has created a powerful patient registry, GRIN, powered by Across Healthcare’s rare disease Matrix platform. This user-friendly platform allows patients, caregivers, clinicians, and researchers the ability to manage health data to elevate patient care, advance research, support clinical trial designs, enhance therapy development with industry partners, and improve diagnosis.

Hereditary Neuropathy Foundation’s (HNF) mission is to increase awareness and accurate diagnosis of Charcot-Marie-Tooth (CMT) and related inherited neuropathies and support people living with CMT and their families with critical information to improve quality of life. HNF only funds research that will lead to treatments and cures. Today it re-launched its Global Registry for Inherited Neuropathies (GRIN) on the Matrix platform by Across Healthcare. The registry’s goal is to acquire, record, and analyze patient-reported data and associated genetic reports, Electronic Health Records (EHRs) and clinical notes to identify the burden, diagnostic journey, and prevalence of disease that will aid scientists in their work toward finding a cure.

“Initiatives such as the HNF registry bring together critical data from patients, caregivers and clinicians, including genetic tests and electronic health records. This information can help inform clinical trials of therapies for the 150,000 people in the US who are living with Charcot-Marie-Tooth disease and have no treatment options available,” said Shoshana Shendelman, CEO & Founder of Applied Therapeutics.

Originally launched in 2013, GRIN has continued to evolve. The data collected has helped HNF and its partners in industry, academia, and government identify previously unknown genotype/phenotype correlations, uncover important comorbidities such as pain or respiratory issues, and target our research spending based on actual patient need and likelihood of success.

“GRIN data has been essential in clinical trial protocol design, site selection, and efficient patient recruitment for the pivotal Phase III clinical study of our lead asset PXT3003, the PREMIER trial, in development for the most common type of CMT, CMT1A. In addition, the robust data collected in GRIN, together with the ongoing CMT&Me digital survey, will enable a better understanding of the burden of disease, comorbidities, and critical patient demographics as we move forward to a potential commercialization of PXT3003 if approved by the FDA. Topline data of the PREMIER trial are expected in the last quarter of 2023.” Xavier Paoli M.Sc. Pharnext, Chief Operating Officer.

HNF had invested an additional $140,000 funding for the maintenance and expansion of GRIN to include clinicians and links to EHRs, and the migration to the Matrix platform was the result of fundraising campaigns and multiple generous benefactors, including an ongoing match campaign from an anonymous donor in the amount of $200,000 ($400,000 total).

“Pharma and biotech investment in developing therapies for CMT is moving faster than ever before as a result of the HNF hosted EL-PFDD meeting with FDA.” said Allison Moore, HNF’s Founder & CEO. “HNF is committed to supporting this development with the critical data needed by industry to characterize this disease and define clinically significant outcome measures that are meaningful to patients by continually improving and expanding our GRIN platform. Furthermore, we are on a path to reach and represent a more diverse patient population and are excited that this new platform is available in seven languages and HNF has expanded resources to reach the underserved and underrepresented patient population.”

“We are humbled and honored to be working with HNF to empower anyone living with CMT and their families to track and give individualized insights through our Matrix platform while simultaneously continuing the legacy and vision of the GRIN platform to provide a robust regulatory grade international registry.” said Jason Colquitt, Across Healthcare’s Founder & CEO.

Learn more on this topic

Related Blog Posts

HNF is Reshaping Drug Repurposing for CMT

HNF is Reshaping Drug Repurposing for CMT

HNF has partnered with Rarebase, a public benefit precision medicine company that has screened a large library of FDA approved small molecules to identify candidates for various types of CMT. Their tech-enabled drug discovery platform is called Function™. There are many published discoveries on the genetic cause of many types of CMT, including an understanding of the basic mechanism of disease and potential targets for FDA-approved drug repurposing. It is this understanding that allows HNF and Rarebase to target the genetic root cause of CMT.

Join the conversation

Leave a Comment


Submit a Comment

Your email address will not be published. Required fields are marked *


Join for notifications on events, campaigns, & news